HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on Ventyx Biosciences (NASDAQ:VTYX) and maintained a $6 price target.
July 30, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating on Ventyx Biosciences and maintained a $6 price target.
The reiteration of a Neutral rating and maintenance of the $6 price target suggests that the analyst does not foresee significant short-term movement in the stock price. This neutral stance indicates a balanced view of the company's prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100